CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

WashingtonSANA-A new study highlighted the potential benefits of popular diabetes drugs on a wide range of health issues including demen ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

Second, DexCom has expanded its product offerings. Last year, it launched Stelo in the U.S., an over-the-counter CGM option that can be used by pre-diabetes patients. This initiative significantly ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

The study involved people with type 2 diabetes who had no history of cancer. They were treated with either a GLP-1, insulin, or metformin during the study, which are used for treating diabetes. The ...

While GLP-1 therapies like Ozempic gain traction, personalized peptide therapies are supporting long-term health goals ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...